The DOI matches its Crossref record.
Insulin-like Growth Factor Binding Protein-1: Recent Findings and New Directions
Abstract
In 1988, insulin-like growth factor-binding protein-1 (IGFBP-1) became the first characterized member of a group of structurally related soluble proteins which specifically bind and modulate the actions of the IGFs. Since then, a wealth of information has accumulated regarding the physiology of this dynamic serum protein. In this review, we update our 1993 summary (Lee PDK et al. Proc Soc Exp Biol Med 204:4-29) of the status of IGFBP-1 research. The IGFBP-1 protein sequence contains 12 N-terminal and 6 C-terminal cysteine residues which are conserved in other mammalian IGFBP-1 sequences and amongst other IGFBPs; both of the cysteine-rich regions are required for optimal IGF binding. The nonconserved IGFBP-1 midregion may act as both a hinge which defines ligand binding characteristics and as a specific target for protease activity. Integrin-binding and phosphorylation sites within the IGFBP-1 sequence have functional significance in vitro, but their physiologic relevance in vivo have not been defined. The human IGFBP-1 and IGFBP-3 genes are contiguous and located in close proximity to the homeobox A (HOXA) gene cluster on chromosome 7. The other IGFBP genes, located on chromosomes 2, 12, and 17, are also associated with HOX clusters, suggesting evolutionary linkage of the IGFBP and HOX gene families. Similarities between the hlGFBP-1 and phosphoenolpyruvate kinase (PEPCK) promoters, including regions conferring insulin, glucocorticoid, and cyclic adenosine-monophosphate responses, are consistent with our previous hypothesis that IGFBP-1 is involved in regulation of glucose metabolism. The tissue-specific patterns of IGFBP-1 gene expression in liver, kidney, decidua, and ovary may be due to stimulation of IGFBP-1 transcription by hepatic nuclear factor 1 (HNF1) proteins. Clinical and basic studies of IGFBP-1 physiology have been aided by several recently developed assay methods. Numerous investigations have confirmed that insulin, via inhibition of IGFBP-1 transcription, is the primary determinant of IGFBP-1 expression both in vitro and in viva IGF-I and IGF-II also have specific inhibitory effects on IGFBP-1 expression. Glucocorticoids and cAMP stimulate IGFBP-1 transcription, but these effects are observed only in conditions of low or absent insulin effect. Other stimulants of IGFBP-1 expression include thyroid hormones and epidermal growth factor. Phorbol ester stimulation of IGFBP-1 expression can supersede the effects of insulin in vitro; however, the mechanism and in vivo correlates of this effect have not been determined. Cytokines and, perhaps, growth hormones may affect IGFBP-1 expression, perhaps by altering the regulatory actions of insulin; this effect may have important clinical relevance. IGFBP-1 expression is upregulated in liver and (nonhuman) kidney during postinjury regeneration. The IGF-inhibitory actions of IGFBP-1 has been confirmed by numerous in vitro studies and several in vivo animal investigations, including administration of recombinant IGFBP-1 and IGFBP-1 transgenic models. IGFBP-1 has been shown to inhibit somatic linear growth, weight gain, tissue growth, and glucose metabolism. Moreover, IGFBP-1 appears to be a primary determinant of free IGF-I levels in serum. Excess levels of IGFBP-1 may contribute to growth failure in intrauterine growth restriction and in pediatric chronic renal failure, while low IGFBP-1 levels are associated with obesity and with cardiovascular risk factors in insulin resistance syndromes. Serum IGFBP-1 measurements may be useful biochemical marker in these pathologic conditions. IGFBP-1 is expressed in decidualized stromal cells of the uterine endometrium and in ovarian granulosa cells. IGFBP-1, together with IGFs, insulin, ovarian steroids, cytokines, and other factors, is involved in a complex system which regulates menstrual cycles, ovulation, decidualization, blastocyst implantation, and fetal growth. Models for the role of IGFBP-1 in female reproductive physiology are presented, and evidence for pathophysiologic roles in pre-eclampsia, polycystic ovarian syndrome, and uterine malignancy are reviewed. Very recent data indicates that IGFBP-1 undergoes regulated expression in human osteoblasts. Limited information also suggests that IGFBP-1 may be present in peripheral neurons, and that serum IGFBP-1 may increase during exercise and in critical ilIness. In summary, two major roles for IGFBP-1 in normal physiology can be constructed from current data: (i) As an “endocrine” factor, IGFBP-1 regulates the bio-availability of serum IGF-I, thereby modulating IGF-mediated tissue metabolism. The dominant regulation of IGFBP-1 expression by meal-related changes in hepatic insulin concentrations provides a dynamic link to substrate availability. (ii) As an autocrine/paracrine factor, IGFBP-1 appears to play a crucial role in the female reproductive system and, in particular, the sequence of events leading from ovulation to implantation to successful fetal outcom
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Igfbp1 has been proposed as an acute regulator of IGF-1 bioactivity 35 and its elevation in association with HB treatment is unclear.”
From Akt-dependent anabolic activity of natural and synthetic brassinosteroids in rat skeletal muscle cells (2011) · cites this paper as [35]
Citations
Cited by
Sorted by citations
Items 301–400 of 536
Cleare, A. J., Sookdeo, S. S., Jones, J. L., O’Keane, V., & MIELL, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6513 · Cited by 20
“Normally, IGFBP-1 is regulated by insulin through direct effects on gene transcription (39, 40) and indirect effects on transcapillary movement out of the circulation (41).”
BackgroundRoelfsema, V., Lane, M. H., & CLARK, R. G. (2000) · Pediatric Nephrology · doi:10.1007/s004670000350 · Cited by 20
Lewitt, M., & Brismar, K. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802135 · Cited by 19
Peterkofsky, B., Gosiewska, A., Wilson, S. M., et al. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0797 · Cited by 19
Dementia: A neuroendocrine perspective
POLLERI, A., Gianelli, M. V., & Murialdo, G. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03343964 · Cited by 20
Insulin-like Growth Factor Binding Proteins in Development
Silha, J. V., & Murphy, L. J. (2005) · Springer eBooks · doi:10.1007/0-387-26274-1_3 · Cited by 18
Liao, S., Vickers, M. H., Taylor, R. S., Fraser, M., McCowan, L. M. E., Baker, P. N., & Perry, J. K. (2017) · HORMONES · doi:10.14310/horm.2002.1747 · Cited by 23
Hellström, A., Sigurdsson, J., Löfqvist, C., Hellgren, G., & Kistner, A. (2020) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2020.02.002 · Cited by 19
The Insulin-Like Growth Factor System and Nutritional Assessment
Livingstone, C. (2012) · Scientifica · doi:10.6064/2012/768731 · Cited by 18
Wasada, T., Kawahara, R., & Iwamoto, Y. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.1039 · Cited by 17
Sequencing analysis of the ghrelin receptor (growth hormone secretagogue receptor type 1a) gene
Vartiainen, J., Poykko, S., Raisanen, T., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500457 · Cited by 18
Fasting Glucose Is a Risk Factor For Breast Cancer
Muti, P. C., Quattrin, T., Grant, B. J. B., et al. (2002) · Cancer Epidemiology and Prevention Biomarkers · Cited by 18
Kaplan, R. C., Strizich, G., Aneke-Nash, C. S., Domínguez‐Islas, C., Bůžková, P., Strickler, H. D., Rohan, T. E., Pollak, M., Kuller, L. H., Kizer, J. R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2779 · Cited by 17
“Insulin in the portal circulation acutely regulates circulating levels of IGFBP-1 by inhibiting the transcription of IGFBP1 in the liver (11), such that circulating IGFBP-1measurements taken after a glucose load are fivefold to 10-fold lower than measurements taken in the fasting state (12).”
BackgroundKaneko, N., Torao, M., Koshino, Y., et al. (2019) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2019.01.001 · Cited by 17
Kaneko, N., Nilsen, T. O., Tanaka, H., Hara, A., & Shimizu, M. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00099.2019 · Cited by 16
“IGFBP-1 is one of the major circulating forms, and its levels are increased when animals are under catabolic conditions, such as nutritional deficiency and stress (36, 37, 56).”
BackgroundEkberg, N. R., Ungerstedt, U., & Brismar, K. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00424.x · Cited by 17
Serum levels of adiponectin and IGFBP‐1 in short children born small for gestational age
Kamoda, T., Nozue, H., & Matsui, A. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02724.x · Cited by 17
Lundin, H. R., Sääf, M., Strender, L., Nyrén, S., Johansson, S., & Salminen, H. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0152-4 · Cited by 17
Maternal-fetal conflict — lessons from a transgene
Giudice, L. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16389 · Cited by 17
“Moreover, while IGFBP-1 regulates minute-to-minute bioavailability of IGF-I (17, 18), the ligand blots in the manuscript by Crossey et al.”
BackgroundSelf-citationGhosh, D., & Sengupta, J. (2004) · PubMed · Cited by 17
Verhaeghe, J., Billen, J., & Lc, G. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1700585 · Cited by 17
“Indeed, insulin is the major determinant of circulating IGFBP-1 levels after birth in humans and experimental animals, with increased levels in type 1 diabetes but suppressed levels under hyperinsulinemic conditions (reviewed by Lee et al. 1997).”
BackgroundFukuda, M., Kaneko, N., Kawaguchi, K., et al. (2015) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2015.04.016 · Cited by 16
“IGFBP-1 is the first member to be identified in humans and is one of major circulating IGFBPs (Lee et al., 1988; Lee et al., 1993,1997).”
BackgroundInfluentialInsulin-Like Growth Factor-1 and Anemia in Older Subjects: The Inchianti Study
Vita, F. D., Maggio, M. G., Lauretani, F., Crucitti, L., Bandinelli, S., Mammarella, F., Landi, F., Ferrucci, L., & Ceda, G. P. (2015) · Endocrine Practice · doi:10.4158/ep14100.or · Cited by 16
“However, although IGFBP-3 is the storage protein for IGF-1 and is able to exert paracrine and autocrine actions on cellular growth via IGF-dependent and IGF-independent mechanisms (35), its role in erythropoiesis is unclear given the lack of additional studies in older individuals.”
BackgroundGhosh, D., Bell, S. C., & Sengupta, J. (2003) · Placenta · doi:10.1016/j.placenta.2003.08.011 · Cited by 16
“The function of IGF-II : IGFBP-1 at fetomaternal interface may involve a delicate balance between invasion [53,54] and its suppression [35,55] to achieve normal placental development [56].”
BackgroundTXNDC5 contributes to rheumatoid arthritis by down-regulating IGFBP1 expression
Li, J., Xu, B., Wu, C., Yan, X., Zhang, L., & Chang, X. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13080 · Cited by 16
“IGFBP1 also binds IGF-1 with high affinity, prolongs the half-life of IGFs, and mediatesthe interactionsbetween IGF and its cell surface receptors to modulate the downstream signaling pathway [25, 26].”
BackgroundAziz, A., Haywood, N. J., Cordell, P. A., Smith, J., Yuldasheva, N. Y., Sengupta, A., Ali, N., Mercer, B. N., Mughal, R. S., Riches‐Suman, K., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00572 · Cited by 16
“From the functional perspective, an inhibitory effect of insulin on hepatic IGFBP1 synthesis 78 has led to IGFBP1 being implicated in glucose regulation (14).”
BackgroundFernqvist‐Forbes, E., Ekberg, K., Lindgren, B. F., & Brismar, K. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00775.x · Cited by 16
“However, the bioavailability and bioactivity of IGF-I is regulated by its binding to six different characterised proteins, IGFBP-1-6 and it is only in its free form that IGF-I is bioactive (Lee et al., 1997).”
BackgroundMori, M., Sumitomo, S., Shrestha, P., et al. (2008) · Oral Medicine & Pathology · doi:10.3353/omp.12.115 · Cited by 16
Wallin, M. K. E. B., Barr, G., Öwall, A., Lindahl, S. G. E., & Brismar, K. (2003) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1016/s1053-0770(03)00152-6 · Cited by 16
Are Growth Factors and Leptin Involved in the Pathogenesis of Premature Adrenarche in Girls?
Güven, A., Cınaz, P., & Ayvali, E. (2005) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2005.18.8.785 · Cited by 16
Maternal-fetal conflict — lessons from a transgene
Giudice, L. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216389 · Cited by 16
Self-citationJanssen, J. A. M. J. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054551 · Cited by 19
“Portal blood insulin levels are thought to be amongst the most potent regulators of IGFBP-1 secretion from the liver [85].”
BackgroundInsulin-Like Growth Factor-1 Bioactivity Plays a Prosurvival Role in Older Participants
Maggio, M. G., Cattabiani, C., Lauretani, F., Bandinelli, S., Vita, F. D., Dall’Aglio, E., Corsonello, A., Lattanzio, F., Paolisso, G., Ferrucci, L., et al. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt045 · Cited by 16
“IGF-1 bioactivity and bioavailability are also influenced by six binding proteins (IGF-binding proteins [IGFBPs]) that also exert independent biological actions (22,23).”
BackgroundKim, Y. A., Ku, S., Kim, Y. A., et al. (2016) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0041-111173 · Cited by 15
“Since the discovery of miRNA (lin-4) in Caenorhabditis elegans [10], miRNAs have been shown to play an important role in cellular signaling, apoptosis, metabolism, development and organogenesis [11 – 15].”
Klevebro, S., Hellgren, G., Pupp, I. H., Wackernagel, D., Hallberg, B., Borg, J., Pivodic, A., Smith, L. E. H., Ley, D., & Hellström, A. (2019) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2019.11.001 · Cited by 16
“Insulin like growth factor binding protein 1 (IGFBP-1) is a major determinant of free IGF-1 availability [13].”
BackgroundTreating Human Meniscal Fibrochondrocytes with hIGF-1 Gene by Liposome
Zhang, H., Leng, P., Wang, Y., et al. (2009) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-009-0870-2 · Cited by 15
“Since hIGF1 is a major chondro-enhancing agent, notwithstanding its attenuated effect on aged cartilage, it would appear a logical choice for gene therapy approaches [4, 5, 7, 12, 16].”
BackgroundPlacental IGF‐I, IGFBP‐1, zinc, and iron, and maternal and infant anthropometry at birth
Akram, S. K., Carlsson‐Skwirut, C., Bhutta, Z. A., et al. (2011) · Acta Paediatrica · doi:10.1111/j.1651-2227.2011.02336.x · Cited by 15
“, (15) have shown that IGFBP-1 has an inverse relationship to the amount of free IGF, suggesting that increases in levels of this binding protein may result in subsequent increases in ligand sequestration.”
BackgroundProduction of recombinant salmon insulin-like growth factor binding protein-1 subtypes
Tanaka, H., Oishi, G., Nakano, Y., et al. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.06.015 · Cited by 15
“Insulin is the major inhibitor of IGFBP-1 production, whereas cortisol stimulates its 77 production (Lee et al., 1993, 1997; Wheatcroft and Kearney, 2009).”
BackgroundGennari, A., Pazos, P., Boveri, M., Callaghan, R., Casado, J., Maurici, D., Corsini, E., & Prieto, P. (2004) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20006 · Cited by 15
Specific cleavage of insulin-like growth factor-binding protein-1 by a novel protease activity
Wang, J., Shafqat, J., Hall, K. E., Ståhlberg, M., Wivall-Helleryd, I.-L., Bouzakri, K., Zierath, J. R., Brismar, K., Jörnvall, H., & LEWITT, M. S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6248-7 · Cited by 15
Troglitazone stimulates IGF-binding protein-1 by a PPARγ-independent mechanism
Hilding, A., Hall, K. E., Skogsberg, J., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00403-0 · Cited by 15
Nonvillous Parts and Trophoblast Invasion
Frank, H., & Kaufmann, P. (2006) · Springer eBooks · doi:10.1007/0-387-26742-5_9 · Cited by 15
Lagha, N. B., Menuelle, P., Seurin, D., et al. (2002) · Connective Tissue Research · doi:10.1080/03008200290000998 · Cited by 15
Crissey, M. A. S., Leu, J. I.-J., Angelis, R. A. D., Greenbaum, L. E., Scearce, M. L., Kovalovich, K. K., & Taub, R. A. (1999) · Hepatology · doi:10.1002/hep.510300520 · Cited by 14
Age-Dependent Regulation of the Acid-Labile Subunit in Response to Fasting-Refeeding in Rats
Kong, S., Baxter, R. C., & Delhanty, P. J. D. (2002) · Endocrinology · doi:10.1210/en.2002-220527 · Cited by 15
Discrepancies in insulin-like growth factor signaling? No, not really
Conover, C. A. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.10.005 · Cited by 14
Self-citationBui, H., Amrani, Y., Deeney, B. T., Panettieri, R. A., & Tliba, O. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.05.006 · Cited by 14
“In addition to being increased in vitro by GC in U2OS/A549 cell lines [43] or hepatocytes [16], increased Bui et al.”
BackgroundInfluentialWłodarczyk, B., Borkowska, A., Włodarczyk, P., Malecka-Panas, E. I., & Gąsiorowska, A. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001297 · Cited by 14
C57BL/KsJ-db/db-ApcMin/+ Mice Exhibit an Increased Incidence of Intestinal Neoplasms
Hata, K., Kubota, M., Shimizu, M., Moriwaki, H., Kuno, T., Tanaka, T., Hara, A., & Hirose, Y. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12118133 · Cited by 14
“Furthermore, hyperinsulinemia was shown to indirectly increase bioavailability of IGF-1 by regulating the expression levels of IGF-binding proteins [38,39].”
BackgroundSouren, N. Y., Paulussen, A. D. C., Steyls, A., Loos, R. J. F., Brandão, R. D., Gielen, M., Smeets, H. J. M., Beunen, G. P., Fagard, R. H., Derom, C. A., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.126 · Cited by 14
Jassal, S. K., von Mühlen, D. G., Barrett-Connor, E. L., & Rosen, C. J. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1973-6 · Cited by 14
Kamoda, T., Saitoh, H., Hirano, T., et al. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01145.x · Cited by 14
Frystyk, J. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.07.001 · Cited by 14
Stabilization of IGFBP-1 mRNA by ethanol in hepatoma cells involves the JNK pathway
Magne, L., Blanc, É., Marchand, A., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.05.018 · Cited by 14
Nutrition-Gene Interactions During Intrauterine Life and Lactation
Hay, W. W. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1999.tb01784.x · Cited by 14
Regulation of Insulin-Like Growth Factor-Binding Protein-1 by Nitric Oxide under Hypoxic Conditions1
Sugawara, J., Suh, D., Faessen, G. H., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6709 · Cited by 14
Self-citationPatel, S., Lochhead, P. A., Rena, G., & Sutherland, C. D. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590611 · Cited by 14
Gan, L., Pan, H., & Unterman, T. G. (2005) · Endocrinology · doi:10.1210/en.2005-0224 · Cited by 14
Cheng, R. Y. S., Birely, L., Lum, N., et al. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320257 · Cited by 14
Self-citationAneke-Nash, C. S., Parrinello, C. M., Rajpathak, S. N., Rohan, T. E., Strotmeyer, E. S., Kritchevsky, S. B., Psaty, B. M., Bůžková, P., Kizer, J. R., Newman, A. B., et al. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13390 · Cited by 13
“Insulin downregulates the hepatic production of IGFBP-1, so individuals developing insulin resistance have decreasing levels of IGFBP-1.”
BackgroundMong, J. L. Y., Ng, M. C. Y., Guldan, G. S., Tam, C. H. T., Lee, E. H. M., Ma, R. C. W., So, W., Wong, G., Kong, A. P. S., Chan, J. C. N., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.186 · Cited by 13
Somatolactogens and diabetic retinopathy
Bermea, K. C., Rodríguez-García, A., Tsin, A. T. C., & Barrera-Saldaña, H. A. (2018) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2018.02.002 · Cited by 13
Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy
Tokunaga, K., Uto, H., Takami, Y., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.032 · Cited by 13
Zhang, P., Suidasari, S., Hasegawa, T., Yanaka, N., & Katô, N. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1629 · Cited by 13
“IGFBP1 is primarily produced and secreted from the liver (15) and binds to insulin growth factors (IGFs), modulating their actions (15).”
BackgroundChanges in gene expression during chemical‐induced nephrocarcinogenicity in the Eker rat
Patel, S. K., Ma, N., Monks, T. J., et al. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10153 · Cited by 13
“In contrast, IGFBP-1 has also been implicated in IGF independent actions including cell motility, protein synthesis, and apoptosis [54].”
BackgroundLewitt, M., Brismar, K., Ohlson, J., et al. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.171r011 · Cited by 13
Li, Y., Wu, S., Huang, J., & Zhao, L. (2024) · The FASEB Journal · doi:10.1096/fj.202302629rr · Cited by 12
“65 Collectively, these results suggested that these DE mRNAs may be closely related to the higher ability of crucian carp to resist hypoxia.”
Sifakis, S., Akolekar, R., Kappou, D., Mantas, N., & Nicolaides, K. H. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2682 · Cited by 12
“Consequently, the effect of IGF-I and IGFBP-1 on PE is more likely to be related to their metabolic effects rather than their actions on placentation.”
BackgroundInfluentialIs There A Place for Adjuvant Therapy in IVF?
Segev, Y., Carp, H., Auslender, R., & Dirnfeld, M. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181dbc53f · Cited by 12
“Lower serum IGF-1 concentrations following pituitary desensitization (30) may account for some of the suboptimal responses to gonadotrophin stimulation.”
BackgroundChen, W., Zhang, Z., Dong, H., & Yan, F. (2016) · Fish Physiology and Biochemistry · doi:10.1007/s10695-015-0195-x · Cited by 12
“The expression pattern in various tissues suggests that goldfish IGFBP-1 may be synthesized locally and modulate the local action of IGFs.”
BackgroundInfluentialPhysiological Regulation of Growth during Social Ascension in a Group-Living Fish
Culbert, B. M., Balshine, S., & Gilmour, K. M. (2019) · Physiological and Biochemical Zoology · doi:10.1086/702338 · Cited by 12
Smith, B. I., Liefeld, A., Vasquez-Hidalgo, M. A., et al. (2021) · Journal of Animal Science · doi:10.1093/jas/skab299 · Cited by 12
Hyperinsulinemia and central adiposity: influence of chronic insulin therapy in type 1 diabetes.
Kabadi, U. M., Vora, A., & Kabadi, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.1024 · Cited by 12
Shi, L., Banerjee, D., Dobierzewska, A., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00289.2015 · Cited by 12
Sarem, Z., Bumke‐Vogt, C., Mahmoud, A. M., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00558 · Cited by 11
Cingel-Ristić, V., van Neck, J. W., Frystyk, J., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1742 · Cited by 11
“induced increase in insulin levels (14).”
Jasinska, A. J., Han, V. K. M., Fazleabas, A. T., et al. (2004) · Journal of the Society for Gynecologic Investigation · doi:10.1016/j.jsgi.2004.03.005 · Cited by 11
Nagashima, H., Maeda-Nakamura, K., Iwashita, K., et al. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0162-5 · Cited by 11
“T. Goto Faculty of Agriculture, Shinshu University, Minamiminowa, Nagano 399-4598, Japan related soluble proteins that speciWcally bind and modulate the actions of insulin-like growth factor-I (IGF-I) and -II (Lee et al. 1997).”
BackgroundMenuelle, P., Babajko, S., & Plas, C. (1999) · Endocrinology · doi:10.1210/endo.140.5.6750 · Cited by 11
“IGFBP-1 is expressed largely in the liver and endometrium, suggesting that it plays some specific role in each organ (14, 15).”
BackgroundMolecular basis of carcinogenesis in diabetic patients (Review)
Matyszewski, A., Czarnecka, A. M., Solarek, W., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2865 · Cited by 10
Chen, Y., Fu, M., Lan, D., et al. (2014) · Asian-Australasian Journal of Animal Sciences · doi:10.5713/ajas.14.0413 · Cited by 10
“Furthermore, IGF-1 can induce the expression of hypoxia inducible factor (HIF1) under hypoxic or ischemic condition, triggering the expression of various target genes that regulate the cellular hypoxic response (Lee et al., 1997; Sugawara et al., 2000; Fukuda et al., 2002; Rajpathak et al., 2009).”
BackgroundTsunawaki, T., Sakai, K., Momomura, M., Wachi, Y., 松澤, 由., & Iwashita, M. (2013) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12078 · Cited by 10
“During pregnancy, IGFBP-1 is produced predominantly by the maternal liver and deciduas, and the fetal liver.(10,11) The effects of IGFBP-1 depend on its total concentration and its posttranslational modifications, such as phosphorylation, proteolysis and polymerization.”
BackgroundYang, G., Chen, B., Sun, C., et al. (2019) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2019.06.001 · Cited by 10
Hasegawa, R., Miura, T., Kaneko, N., et al. (2020) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2020.113606 · Cited by 10
Eaves, L. A., Bulka, C. M., Rager, J. E., Gardner, A. J., Galusha, A. L., Parsons, P. J., O’Shea, T. M., & Fry, R. C. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.137469 · Cited by 10
Huang, X., Ye, H., Huang, H., Liu, A., & Feng, B. (2015) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2015.04.014 · Cited by 10
Zhai, W., Zhang, J., Shi, Z., et al. (2012) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2012.01.007 · Cited by 10
Novak, E. J., Örtqvist, E., Nord, E., Edwall, L., Hampe, C. S., Bekris, L. M., Persson, B. E., & Lernmark, Å. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.1019 · Cited by 10
Heald, A. H., Anderson, S. G., Vyas, A., Siddals, K. W., Patel, J. V., Yates, A. P., Bhatnagar, D., Prabhakaran, D., Hughes, E. A., Rudenski, A. S., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1871-7 · Cited by 10
“In this context, it is likely that the principal determinant of increased postprandial IGF-I bioavailability is IGFBP-1, owing to the rapid fall in IGFBP-1 following food intake [40, 41].”
BackgroundZhou, H., Zhuang, W., Huang, H., Ma, N., Lei, J., Jin, G., Wu, S., Zhou, S., Zhao, X., Lan, L., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154428 · Cited by 9
Fernández-Pereira, C., & Agís‐Balboa, R. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062561 · Cited by 12
Chunfen, L., Meng, H. E., Cui, Y., Peng, Y., Liu, J., & Yueli, Y. U. N. (2021) · Integrative Zoology · doi:10.1111/1749-4877.12550 · Cited by 10
Desmopressin increases IGF-binding protein-1 in humans.
Catrina, S., Rotarus, R., Botusan, I. R., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0662 · Cited by 9
Włodarczyk, B., Gąsiorowska, A., & Malecka-Panas, E. I. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001073 · Cited by 9
Glucagon and GLP-1 stimulate IGFBP-1 secretion in Hep G2 cells without effect on IGFBP-1 mRNA
Hilding, A., Möller, C., & Hall, K. E. (2002) · Growth Hormone & IGF Research · doi:10.1054/ghir.2001.0262 · Cited by 9
Souren, N. Y., Zeegers, M. P., Janssen, R. G. J. H., Steyls, A., Gielen, M., Loos, R. J. F., Beunen, G. P., Fagard, R. H., Stassen, A. P. M., Aerssens, J., et al. (2008) · Twin Research and Human Genetics · doi:10.1375/twin.11.5.505 · Cited by 9
Cha, J., Dey, S. K., & Lim, H. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00038-7 · Cited by 12
McCarty, M. F. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(02)00215-3 · Cited by 9
New metabolic‐endocrine risk markers in endometrial cancer
Stoll, B. A. (1999) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08290.x · Cited by 9
Lackey, B. R., Gray, S. L., & Henricks, D. M. (2000) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22360.x · Cited by 9
Metadata
- Authors
- Lee, P. D. K., Giudice, L. C., Conover, C. A., & Powell, D. R.
- Affiliations
- Mayo Clinic (US)
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 1997-12-01
- Volume
- 216
- Issue
- 3
- Pages
- 319-357
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2036466897
- Cited by
- 523
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 11 · 2018: 10 · 2017: 19 · 2016: 16 · 2015: 16 · 2014: 11 · 2013: 17 · 2012: 14
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- IGFBP-1, insulin-like growth factor, IGF binding, cysteine-rich region, protease cleavage, integrin binding, phosphorylation sites, IGFBP-3, chromosome 7, glucose metabolism, glucocorticoids, cyclic AMP, tissue-specific gene expression
- MeSH terms
- Amino Acid Sequence, Animals, Bone and Bones, Cartilage, Connective Tissue, Female, Gene Expression Regulation, Genitalia, Female, Genitalia, Male, Humans, Kidney, Liver, Male, Molecular Sequence Data, Organ Specificity, Substrate Specificity, Insulin-Like Growth Factor Binding Protein 1, Evolution, Molecular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review